Description
Relamorelin is a synthetic, centrally penetrant, selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR). It is potentially useful for the treatment of diabetic gastroparesis, chronic idiopathic constipation, and anorexia nervosa. It is a pentapeptide and an analogue of ghrelin. It produces increases in plasma growth hormone, prolactin, and cortisol levels, and increases appetite in humans. It is under development by Rhythm Pharmaceuticals and is in phase II clinical trials